• Mark McKenna storms back with Mirador and eyes the development landscape

  • Apr 23 2024
  • Duración: 25 m
  • Podcast

Mark McKenna storms back with Mirador and eyes the development landscape Por arte de portada

Mark McKenna storms back with Mirador and eyes the development landscape

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In one of the biggest financings of the year so far, former Prometheus Biosciences Inc. CEO Mark McKenna helped raise $400 million to launch a new company, Mirador Therapeutics Inc. He didn’t sit on the sidelines for long after Merck & Co. Inc. bought Prometheus for $10.8 billion in 2023. He recruited key Prometheus executives to focus on Mirador’s genetic approach to drug discovery and precision medicine. McKenna said there was too much left undone to just hang back. In this BioWorld Insider episode, he talks about the new company and the multi-billion-dollar drugs that he believes provide sub-optimal efficacy compared to the tailor-made therapies he wants to develop. He also has deep insights into drug pricing and why the investment market is so tough on companies that don’t have A-plus science and teams.
    Más Menos
activate_primeday_promo_in_buybox_DT
Más Menos

Lo que los oyentes dicen sobre Mark McKenna storms back with Mirador and eyes the development landscape

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles